Table 1.
Antiepileptic drugs prescribed to adults diagnosed with JME [15].
Table 2.
Overview of the definitions used for the diagnosis of DRE in the included studies.
Fig 1.
Illustration of the progression of our study, outlining the quantity of citations found in titles and abstracts, the removal of duplicates, inclusion of full texts, as well as the exclusion criteria and reasons for exclusions.
Fig 2.
Review of authors’ judgements about each risk of bias item presented as percentages across all included studies.
Fig 3.
1 ASM Resistant VS ASM Non-Resistant, outcome: 14 Febrile Seizures.
Fig 4.
1 ASM Resistant VS ASM Non-Resistant, outcome: 5 Psychiatric disorders.
Table 3.
Study quality and characteristics.
Fig 5.
Meta‐analysis of the prevalence of refractory juvenile myoclonic epilepsy (JME).
The proportion of subjects who were refractory is displayed on the x‐axis. A total of 25 studies describing seizure outcome in 3051 individuals with JME were included. CI, confidence interval; RE, random effects. References denoted as ‘Study’ are available in the S5 Table.
Fig 6.
Meta-regression analysis of juvenile myoclonic epilepsy refractoriness based on publication year.
We plotted the proportion of refractory subjects per study against the publication year. Each study is depicted by a circle, and the circle’s size corresponds proportionally to the sample size. Additionally, a meta-regression trend line with a 95% confidence interval (represented by dotted lines) is illustrated as a solid line.
Table 4.
ASMs resistant risk factors in JME patients.